Background. Wingless-activated medulloblastoma (WNT MB) represents a well-characterized molecular variant accounting for 10-15% of all MB and is associated with a favorable clinical outcome. Patients with localized WNT MBs could benefit from de-intensification of combined treatment, which would require an accurate diagnosis of these tumors. However, despite the presence of molecular features related with a WNT MB signature (nuclear ß-catenin immunoexpression, CTNNB1 mutation, and monosomy 6), a prompt and reliable diagnostic verification of these tumors is not yet feasible. Methods. In the current study, we analyzed 78 samples of WNT MB treated in a single institute through genomewide DNA methylation and targeted next generation sequencing to elaborate an optimal method for WNT MB molecular verification. Results. We found that DNA methylation profiling discloses significant advantages for molecular diagnostic of WNT MB. All other "routine" methods applied, such as ß-catenin immunohistochemistry, CTNNB1 mutation analysis, and detection of monosomy 6, failed to identify all WNT MB cases. Survival analysis revealed that application of a reduced radiotherapy protocol for WNT MB treatment had no influence on patients' survival. Only one patient died due to local relapse but recurrent tumor was pathologically and molecularly diagnosed as a secondary glioblastoma.
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It is well known that the histological entity medulloblastoma (MB) comprises distinct histological variants and molecular subgroups. According to the current international consensus, MB can be classified into 4 main molecular subgroups (Wingless [WNT] , Sonic hedgehog [SHH] , Group 3, and Group 4) based on expression profiles, DNA methylation data, or other genetic alterations. [1] [2] [3] [4] [5] Moreover, this molecular MB classification more accurately predicts patients' outcomes than clinical and histological patterns alone. 1, 3, 6, 7 The WNT-activated MB subgroup represents a well-characterized tumor variant accounting for 10-15% of all MB. [1] [2] [3] [4] [5] [6] [7] These tumors are genetically defined by activating mutations in CTNNB1 often accompanied by monosomy 6. Other frequently occurring mutations in WNT MB include TP53, DDX3X, SMARCA4, or other alterations in chromatin remodeling genes. Pediatric WNT MB are associated with good treatment response and a favorable outcome, 1, 3, [6] [7] [8] [9] [10] [11] [12] and these tumors are considered as molecularly homogeneous MB variant in comparison to SHH and Groups 3/4 MB, which in turn include a few molecular variants with different clinical courses. 2, 6, 7 Moreover, upcoming clinical trials for patients with localized WNT MBs have suggested a reduction or de-intensification of treatment for these tumors, mostly through reduction of craniospinal irradiation (CSI) dose or using a chemotherapy only approach. [13] [14] [15] However, despite the presence of distinct features related to a WNT MB signature, a prompt and reliable molecular identification of these tumors in routine neuropathological practice is not yet feasible. 4, 11 In the current study, we aimed to analyze a representative cohort of WNT MB treated in a single institute through genome-wide DNA methylation, copy number profiling, and targeted next-generation sequencing (NGS) [16] [17] [18] in order to elaborate an optimal method for WNT MB molecular verification. In addition, an optimal risk-adapted treatment of patients with WNT MB was applied and evaluated.
Materials and Methods

Patient Population
We performed a molecular screening (see below) in a cohort of 564 CNS cerebellar tumors histologically diagnosed as "medulloblastoma" based on the 2016 WHO classification of tumors of the central nervous system. 4 All tissue samples were obtained from pediatric patients (ages from 0 to 17 y) treated at the Burdenko Neurosurgical Institute in Moscow (Russia) between January 1, 1997 and January 1, 2016. Informed consent was obtained from all patients' parents or their other relatives/caregivers. This retrospective study was conducted under the auspices of the Ethics Committee of the Burdenko Neurosurgical Institute (Ethical vote number 563/6-16) in compliance with the rules of the Russian Federation and the regulations of the Health Insurance Portability and Accountability Act, and in adherence to the tenets of the Declaration of Helsinki. Treatment details and follow-up data were available for all patients (see Results). DNA methylation profiling detected WNT MB in 78/564 samples (14%). These WNT MBs were subjected to further analyses within this study. The follow-up analysis was stalled on January 1, 2018 (the endpoint of follow-up). Sixteen WNT MBs from the current tumor set were included in our previous study where data of methylation analysis and whole exome sequencing (WES) were combined. 2 In addition, 27 WNT MB samples were included in our previous report comparing data of methylation profiling and NanoString technologies. 17 
DNA Methylation Profiling
DNA was extracted from tumors and analyzed using either Illumina Infinium HumanMethylation 450k or 850k/ EPIC BeadChip arrays as previously described. 6, 7, 16, 17 All DNA methylation analyses were performed in R version 3.3.0. Raw signal intensities were obtained from IDAT files using the minfi Bioconductor package version 1.18.2. Each sample was individually normalized by performing a background correction (shifting of the 5% percentile of negative control probe intensities to 0) and a dye-bias correction (scaling of the mean of normalization control probe intensities to 10 000) for both color channels. No further normalization or transformation steps were performed, and standard beta-values were used for downstream methylation analyses. The following criteria were applied to filter out probes prone to yield inaccurate methylation levels: removal of probes targeting the X and Y chromosomes (n = 11 551), removal of probes that overlap common single nucleotide polymorphisms (dbSNP132 Common) within the cytosine-phosphate-guanine site or the following base (n = 7998), and removal of probes not mapping uniquely to the human reference genome (hg19) (n = 3965). To enable comparability between the Illumina Infinium HumanMethylation 450k and 850k/EPIC arrays, we removed all probes not represented on the 450k array (n = 32 260). In total, 428 799 probes were kept for analysis.
In order to consider distinct molecular signatures, we performed unsupervised clustering of DNA methylation data generated for all 564 MBs. In addition, we repeated unsupervised clustering only for samples which were classified as WNT MB. For unsupervised hierarchical clustering,
Importance of the Study
WNT MB represents a molecular variant which is associated with a good treatment response and favorable clinical outcomes. Patients with WNT MB are appropriate candidates for a reduction or de-intensification of therapy. However, a prompt and clinically reliable molecular identification of these tumors in routine neuropathological practice is not yet feasible. Hence a comprehensive molecular analysis of a representative WNT MB series disclosed that DNA methylation analysis is a method of choice for molecular tumor diagnosis which may help further clinically relevant stratification of the patients.
we selected the 10 000 most variably methylated probes across the dataset (SD > 0.242). Distance between samples was calculated using Pearson correlation coefficient as the distance measure. Average linkage was used to generate dendrograms. The same distance matrix was used to perform the t-distributed stochastic neighbor embedding (tSNE) analysis using the Rtsne package version 0.11. 17 The following nondefault parameters were used: theta = 0, is_ distance = T, pca = F, max_iter = 10 000. Methylation probes in the heatmap representation were reordered by hierarchical clustering using Euclidean distance and average linkage. Copy number profiles were generated using the 'conumee' package for R (https://www.bioconductor.org/ packages/release/bioc/html/conumee.html). 16, 17 To evaluate the methylation status of the O 6 -methylguanine-DNA methyltransferase (MGMT) promoter region, we evaluated beta-values of probes cg12434587 and cg12981137 using the MGMT_STP27 logistic regression model. 16 Targeted Next-Generation Sequencing Targeted DNA sequencing was performed for all 78 WNT MB tumors and matching normal blood. Molecular barcode-indexed ligation-based sequencing libraries were constructed using 200 ng of sheared DNA. Libraries were enriched by hybrid capture with custom biotinylated RNA oligo pools covering exons of 130 cancer-associated genes. 18 Paired-end sequencing was performed using the NextSeq 500 sequencer (Illumina). Sequence data were mapped to the reference human genome (currently GRch37 is applied) using the Burrows-Wheeler Aligner and were processed using the publicly available SAM (Sequence Alignment/Map) tools. CTNNB1, APC, and TP53 mutations were also assessed with residual DNA from the same pool used for sequencing by polymerase chain reaction followed by direct Sanger sequencing of the corresponding exons.
Statistics
The distributions of overall survival (OS) and progression-free survival (PFS) were calculated according to the Kaplan-Meier method using the log-rank test for significance. PFS was calculated from the date of diagnosis until tumor recurrence or last contact for patients who were free of disease. OS was calculated from the date of diagnosis until death of patient from disease or last contact for patients who were still alive. For multivariate analysis, Cox proportional hazards regression models were used. Estimated hazard ratios are provided with 95% confidence intervals and a P-value from the Wald test. Tests with a P-value below 0.05 were considered significant.
Results
Clinicopathological Characteristics of Pediatric WNT MB
Molecularly identified pediatric WNT MB occurred in patients aged 5-17 years (median: 10 y), with a clear preponderance of female patients (63% vs 37% for male; male:female ratio = 0.6:1). All tumors were localized in the fourth ventricle and involved neighboring parts of its floor. At neuroradiological examination, WNT MB appeared as cerebellar midline masses, frequently in contact with the dorsal brainstem and spreading into cerebellopontine cisternae. All 78 WNT MB patients were operated upon and gross total tumor resection was achieved in 39/78 (50%) of cases (no residual tumor after the centralized neuroradiological review). For the other 39 patients, near total resection was established because small tumor remnants (<1.5 cm 2 ) were identified at the postoperative neuroradiological examination. However, we did not find any association between patients' survival and volume of tumor resection (data not shown).
Most patients (66/78; 85%) revealed M0 stage at initial presentation and only 12/78 (15%) cases were initially diagnosed at M2-3 stages. After the operation, all patients received combined treatment with 3 following regimens, wherein the volume of tumor resection was not taken into an account for planning of the therapy:
1. Forty patients with M0 at diagnosis and treated mostly before the year 2003 received HIT-based radiochemotherapy protocols (1991 or 2000) in standard doses (ie, CSI with 36 Gy to the neuroaxis and 56 Gy to the primary tumor site followed with 6-8 cycles of maintenance chemotherapy including vincristine, CCNU, and cisplatin). 2. Twenty-six patients with M0 who were treated predominantly after the year 2003 received reduced radiotherapy protocol where CSI dose was lowered to 23-24 Gy and followed either with 4-8 cycles HIT maintenance chemotherapy (14 patients) or high-dose chemotherapy with stem cell rescue according to St Jude protocol (12 patients). 13 Treatment modalities (1) and (2) were randomly chosen. 3. Twelve patients at M2-3 stages received initially 2 cycles of HIT-SKK regimen with intraventricular methotrexate injection followed by hyperfractionated radiotherapy and 4 cycles of HIT maintenance chemotherapy.
One patient who received the St Jude protocol died 16 months following operation due to complication of therapy (neutropenia, sepsis, multi-organ failure) without patterns of tumor recurrence. Tumor eventually recurred in 3 patients (19, 36 , and 38 months after operation, respectively) while all these patients were initially at M0 stage. One patient with early recurrence received reduced radiotherapy according to St Jude protocol (CSI 23 Gy; highdose chemotherapy) and developed small metastatic foci in both lateral ventricles. He was re-irradiated, received chemotherapy in "recurrence" regimen, and is still alive with OS of 48 months. Two other patients with recurrent disease received "standard" HIT-based protocol (CSI 36 and local 56 Gy). One of them disclosed spinal tumor dissemination (successfully treated with chemotherapy alone; alive for 78 months), but another patient developed local tumor recurrence only. This patient was operated repeatedly and re-irradiated. However, pathological and molecular analyses of the recurrent tumor sample revealed a secondary glioblastoma (GBM) (see below for details). The patient died due to local disease progression.
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All remaining 74 patients (95%) are still alive without tumor recurrence within 30-256 months after the operation. The 5-year PFS was 96% and 5-year OS was 98% (and 100% after an exclusion of 2 patients who succumbed to unrelated deaths). No differences in PFS and OS were observed between the 3 different regimens applied including all branches of chemotherapy (P = 0.58 for PFS and 0.98 for OS) (Fig. 1A, B) .
Histopathologically, all 78 tumors analyzed disclosed similar microscopic appearance with typical classic morphology, and there were no other histological MB variants in this WNT cohort. Beta-catenin immunohistochemistry disclosed nuclear protein accumulation in >5% of nuclei in 60/78 (77%) WNT MB. The remaining 18 (23%) tumors disclosed only cytoplasmic ß-catenin expression.
DNA Methylation Patterns, Cytogenetic Alterations, and Data of Mutational Analysis
All 78 WNT MBs were analyzed by DNA methylation arrays and data were compared with DNA methylation profiles of 486 MBs representing the other 3 molecular subgroups. 7, 16, 17 Unsupervised clustering and tSNE analyses of MB DNA methylation profiles clustered all 78 WNT samples separately from all other MB molecular subgroups, as expected (Fig. 1C) . No additional subclusters within the WNT MB cohort were detected. All molecular allocations remained stable even when we used various combinations of differentially methylated cytosine-phosphate-guanine sites (not shown), confirming that the DNA methylation data are robust and reliable to discriminate between different molecular variants of MBs. In addition, we performed unsupervised clustering analysis for the 78 WNT MB samples only (Fig. 1D ). Tumors were evenly distributed and did not form distinct subclusters correlating with clinical or molecular differences, including mutational landscape (with and without CTNNB1 mutations; see below). MGMT methylation was not detected in this WNT MB cohort. Twenty-seven WNT MBs from the current tumor set (all harboring CTNNB1 mutations) were also analyzed previously with the NanoString method, 17 and all 27 disclosed WNT-associated gene expression signatures, thus confirming a good compatibility of DNA-based and RNA-based techniques, respectively.
We also analyzed copy number aberrations (CNAs) in WNT MB using the methylation data. All WNT MBs revealed various CNAs and the number of chromosomal aberrations varied from 1 to 11 per tumor (mean = 2.1 ± 0.8). A vast majority of WNT MBs (70/78; 90%) revealed monosomy 6, which was a single CNA in 49/70 (70%) of these tumors. Other recurrent aberrations included gain of 19, detected in 14/78 (18%) cases or aberrations on chromosome 17 (including i(17q)) in 10/78 (12%) WNT MBs. A combination of monosomy 6 and i(17q) was found in 5 samples. Tumors without prototypic 6 losses showed variable nonrecurrent aberrations.
Using targeted NGS, we analyzed accessible amounts of tumor and blood DNA for all 78 WNT MBs. Single somatic nucleotide variants (SNVs) and small insertions/deletions (indels) were detected across all these samples, with individual tumor SNV counts ranging from 2 to 9 per tumor (mean = 4.3 ± 1.7). Recurrent gene mutations (more than 10% of samples sequenced) included CTNNB1 (72/78; 92%; 70 SNVs involving exon 3 and 2 indels), DDX3X (25/78; 32%), SMARCA4 (20/78; 26%), KMT2D (16/78; 21%), and TP53 (12/78; 15%). All remaining nonrecurrent mutations were scattered throughout this WNT MB cohort. Three out of 6 WNT MB tumors that had no CTNNB1 mutations harbored homozygous APC aberrations (p.2813_2814del; p.A614_F615 del/ins and c.2103dupG:p.M701fs; all were germline relevant). However, none of these patients had clinical features of "brain tumor-polyposis syndrome 2. " No APC germline mutations were identified in patients who had CTNNB1 mutations in their tumors, but 3 WNT MBs with CTNNB1 mutations also revealed somatic heterozygous APC alterations (two 5265_5268GTCG non-frameshift substitutions and one p.G253S SNV). The other 3 tumor samples without CTNNB1/APC mutations disclosed various heterozygous mutations in SMARCA4, SMARCA2, and KMT2D, respectively. All 12 TP53 mutations were found in association with CTNNB1 alterations and no germline TP53 alterations were found. Eleven of these somatic TP53 mutations were heterozygous and they were not associated with loss of 17p. However, a remaining sample disclosed a somatic homozygous TP53 alteration (c.A377G:p. Y126C) accompanied with i(17q). Finally, 7 (9%) tumors with CTNNB1 alterations disclosed also concomitant SHHassociated mutations in PTCH1 (3), SMO (3), and GLI2 (1), which is in line with findings reported recently. 19 We also compared results of targeted NGS and WES analyses for 16 WNT MBs which were investigated with both of these methods simultaneously (14 tumors with CTNNB1 and 2 with APC mutations). 2 As a result, we identified a similarity of the mutational landscapes detected with both these techniques, and no additional recurrent mutations were discovered by comprehensive WES analysis. Six CTNNB1 wild type (wt) WNT MBs were also analyzed with the NanoString method (a CodeSet 22 platform) and all 6 disclosed an elevated expression of 5 WNT-associated discriminatory genes. 17 In addition, we screened carefully the results of NGS profiling obtained for 452 non-WNT MBs which were included in the reference set (123 SHH MBs, 141 Group 3 MBs and 188 Group 4 MBs, respectively). No one CTNNB1-mutant tumor was identified in this reference MB cohort.
Beta-catenin nuclear positivity (>5% of the cells) was detected in only 60/72 (82%) WNT MBs harboring a CTNNB1 mutation. All remaining samples, including 12 CTNNB1 mutant and 6 CTNNB1 wt cases, revealed only cytoplasmic protein expression. Monosomy 6 was also associated with CTNNB1 alterations and was detected in 66/72 (92%) of CTNNB1 mutant WNT MB in comparison to 4/6 CTNNB1 wt MB (67%). Overall, only 60/78 (77%) of WNT MB disclosed a combination of all "prototypic diagnostic patterns" (ie, nuclear ß-catenin positivity, CTNNB1 alteration, and monosomy 6). The remaining 18 WNT MB disclosed the following combinations of these "prototypic" patterns: (i) CTNNB1 mutation and 6 loss without ß-catenin positivity (6/78; 8%); (ii) CTNNB1 mutation in absence of 6 loss and ß-catenin expression (6/78; 8%); (iii) isolated monosomy 6 (4/78; 5%); and (iv) none of these diagnostic features (2/78; 2%) (Table 1; Supplementary Fig. 1) .
Two WNT MBs which disseminated after surgery and radiochemotherapy but were successfully managed with a second-line chemotherapy disclosed monosomy 6 and heterozygous mutations in CTNNB1, TP53, and DDX3X. In contrast, the primary tumor of the deceased patient with local 
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disease recurrence showed a few chromosomal alterations (including a combination of monosomy 6 and i(17q); see Supplementary Fig. 2B) , and a homozygous somatic mutation of TP53 in combination with heterozygous somatic alterations of CTNNB1, DDX3X, SMARCE1, and PTEN. However, epigenetic profile generated for recurrent tumor (which appeared histologically as a homogeneous small-cell neoplasm) was designated as "pediatric glioblastoma RTK1 (or mid-line high-grade glioma)" according to our current classification ( Supplementary Fig. 2A ). 20 Cytogenetic profile of this tumor revealed MET gene amplification and homozygous deletions of CDKN2A and PTEN (Supplementary Fig. 2C ). Mutations identified in this "secondary GBM" included somatic mutations of ALK, BRCA2, NF1, and SETD2, which in turn were not determined in the primary WNT MB.
Discussion
WNT MB is a well-defined molecular and clinically relevant variant of MB, which has been introduced in the current version of the WHO CNS tumor classification. [1] [2] [3] [4] [5] These tumors predominantly carry a mutation in exon 3 of the CTNNB1 gene which prevents degradation of the protein and shuttling to the nucleus, resulting in activation of the WNT pathway and its downstream targets and further tumor development. 2, 8, 10, 11 In rare cases that are wild type for CTNNB1, germline mutations in APC (sometimes in association with brain tumor-polyposis syndrome 2) can be responsible for WNT MB formation. 21, 22 WNT MB patients usually reveal excellent clinical outcomes, suggesting a favorable biological behavior of this MB variant and their high sensitivity to standard treatment protocols. 1, 3, [6] [7] [8] [9] [10] Perhaps it could be related with paracrine signals driven by mutant β-catenin in WNT MB, which induce a fenestrated tumor vasculature and lack of blood-brain barrier that permits the intratumoral accumulation of chemotherapeutic agents and, consequently, a good therapeutic response. 23 Correspondingly, these patients have been proposed as optimal candidates for de-escalating therapy and therefore a secure selection of WNT MB patients is of critical importance for upcoming clinical trials. [13] [14] [15] In the current study, all WNT MBs were molecularly identified by the currently elaborated diagnostic algorithm based on methylation tumor DNA profiling. 16, 17 Based on DNA methylation, no additional molecular subtypes of WNT MB were identified, confirming their epigenetic homogeneity as noted before. 2, 6, 7 All patients with molecularly detected WNT MBs were treated in a single institute and stratified on a single clinical parameter (M stage). Outcomes after applied treatment protocols are in line with previous reported outcomes for WNT MB patients with only a few events and 5-year OS reaching 100% (excluding 2 cases with unrelated deaths).
A robust method for accurate and reproducible molecular identification of WNT MB within routinely prepared formalin-fixed paraffin embedded MB specimens is a very important point for patient stratification in a clinical setting. 4, 11 However, there is no consensus what the optimal method for correct verification of WNT MBs is, and it has therefore been suggested that at least 2 different methods should be applied for these purposes. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 17, [22] [23] [24] [25] Moreover, most of these methods are not robust enough to accurately and comprehensively identify MBs with WNT molecular signature. For instance, interobserver differences for quantitative and qualitative designation of ß-catenin positivity have been reported, resulting in a number of cases with debatable staining patterns and reliable amount of positive nuclei that are possibly incorrectly categorized. 3, 10, 11 In the current study, only 77% of WNT MBs classified by DNA methylation were ß-catenin positive and their nuclear negativity was noted even in tumors harboring a CTNNB1 mutation.
Various techniques have been proposed for identification of monosomy 6 in the setting of MB molecular diagnostics (fluorescence in situ hybridization, multiplex ligationdependent probe amplification, genome-wide inversion profiling, comparative genomic hybridization microarrays), which have shown variable diagnostic yield and clinical significance. 2, 3, 6, 7, 11, 12, 24 Monosomy 6 was detected in 90% of WNT MBs included in the current cohort, suggesting that this molecular pattern cannot be applied implicitly as a unique single marker for WNT MB diagnostic verification.
Mutation of CTNNB1 is a highly specific molecular pattern of WNT MB, but it cannot be considered a "gold standard" for comprehensive verification of these tumors. It has been found (and confirmed by the current findings) that about 10% of tumors molecularly identified as WNT MBs do not have a CTNNB1 mutation. 2, 6, 7, 21, 22 Instead, they harbor either APC mutations, often already present in the germline, or other alterations that should be clarified further. 2, 21, 22 Moreover, in a subset of WNT MB, CTNNB1 alteration was detected simultaneously with SHH-associated mutations (PTCH1, SUFU, SMO), making a distinct molecular verification questionable without additional analyses. 19 The RNA-based NanoString method applying a CodeSet of 22 discriminatory genes is another robust method for identification of various MB molecular subgroups. 25 However, as we recently have shown by comparative analysis of DNA methylation and CodeSet assays, some samples classified as WNT MB by the NanoString technology were reclassified by DNA methylation as HGNET-BCOR (highgrade neuroepithelial tumor-B-cell lymphoma 6 corepressor) with a prototypic BCOR duplication. 17, 26 Consequently, we recommend DNA methylation profiling using the Illumina EPIC (850k) BeadChip array as the most accurate and robust method for WNT MB classification and patient stratification in future clinical trials. This assay should be adopted and optimized in most major neuro-oncology centers, whereas smaller laboratories may consider sending tissues for analysis to these larger centers. Another important point is elaboration of the optimal treatment strategy for children with WNT MB in settings of upcoming trials, which would be universally suitable for patients having variable clinical parameters and tumor stages. [13] [14] [15] Our current experience showed that patients with WNT MB harboring M0 stage at diagnosis could be an optimal target for de-escalation of radiotherapy, regardless of the tumor resection volume. Reduction of the radiotherapy doses for a tangible WNT MB patients' cohort had no influence on their clinical outcomes, which were in turn absolutely similar with those revealed after standard treatment protocols were applied. Application of high-dose chemotherapy is not looking as an optimal modality taking into an account its high toxicity and side effects. Patients with initially advanced tumor stages were successfully treated with adjuvant HIT-SKK schemes followed by intensified protocols of radiotherapy, thus suggesting a benefit of this treatment approach for WNT MB at the advanced stages.
Only a single dramatic treatment failure was detected in a patient harboring a non-germline but homozygous TP53 alteration accompanied with 17p loss. However, an analysis of the locally recurrent tumor sample revealed a presence of secondary malignancy harboring a molecular profile of pediatric receptor tyrosine kinase 1 (RTK1) GBM. Recently, a comprehensive molecular analysis has identified a subset of 5 MBs (initially interpreted by radiology and histology as locally recurrent tumors) which were diagnosed further as secondary GBMs developed after radiotherapy. 27 These secondary malignant gliomas revealed a proneuronal expression profile and complex alterations in PDGFRA. Moreover, molecular alterations observed in primary MBs were not shared by their respective patient-matched secondary GBMs, confirming their distinct origin. However, all these secondary GBMs developed after treatment of SHH and Group 3 MBs but not WNT-activated tumors. It is well known that somatic TP53 mutations (predominantly heterozygous) were detected frequently in WNT MB but they were not correlated with tumor prognosis, in contrast to TP53 mutant SHH MBs where such alterations are frequently either germline or accompanied with 17p aberrations. 28, 29 Correspondingly, it is tempting to draw a suggestion that biallelic inactivation of TP53 suppressor function in this fatal WNT-activated MB could underlie a possible development of posttreatment secondary malignancy (although not bearing TP53 alteration). Nevertheless, only closer examination would be useful to clarify a distinct significance of TP53 biallelic alterations for clinical outcomes of WNT MB patients as well as for development of posttreatment GBMs.
In conclusion, DNA methylation analysis is an accurate and robust tool for WNT MB molecular diagnosis, which could be considered as a method of choice for further clinically relevant stratification of MB patients, perhaps in combination with the other molecular techniques for confirmation. We could also recommend an integrated molecular analysis for all samples of recurrent MBs as a useful approach for verification of secondary posttreatment malignancies. Patients with localized WNT MBs could benefit from de-intensification of CSI, and further comprehensive examination of opportunities for their treatment de-escalation is warranted in independent validation sets and future clinical trials.
